WT1 TCR-transduced T-cell therapy - Takara Bio

Drug Profile

WT1 TCR-transduced T-cell therapy - Takara Bio

Alternative Names: WT1 antigen-specific RetroNectin TCR gene therapy - Takara Bio; WT1 antigen-specific TCR-gene-transduced autologous lymphocytes - Takara Bio

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takara Bio
  • Developer Mie University; Takara Bio
  • Class T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Japan (SC)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Second-line therapy or greater) in Japan (SC)
  • 03 Dec 2016 Efficacy and safety data from a phase I trial in acute myeloid leukaemia and myelodysplastic syndrome presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top